drugset
drugset / Trial / NCT04049123

A Study of LY900014 in Healthy Chinese Participants

NCT04049123 ↗

Phase 1 Completed 15 enrolled Eli Lilly and Company
RandomizedCrossoverSingle-blindBasic science

Summary

The purpose of this study is to evaluate a new formulation of insulin lispro, LY900014, which is a drug that lowers blood sugar. The study will look at how the body processes LY900014 and the effect of LY900014 on blood sugar levels. For each participant, the study will consist of 3 periods and will last about 51 days.

Timeline

Start
2019-11-18
Primary completion
2020-10-23
Completion
2020-10-23

Drugs

EvaluationDrugModalityDoseRoute
Comparator Insulin Lispro Protein / enzyme biologic 7 iu Subcutaneous
Comparator Insulin Lispro Protein / enzyme biologic 15 iu Subcutaneous

Indications

No indication recorded.